C4 Therapeutics (CCCC) Cash from Operations (2019 - 2026)

C4 Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 29944000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 10.04% year-over-year to 29944000.0; the TTM figure through Mar 2026 stood at 95353000.0 (down 18.71% YoY), while the FY2025 annual figure was 98694000.0, down 51.47% from the prior year.
• Cash from Operations was 29944000.0 for Q1 2026 at C4 Therapeutics, down from 22145000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 4974000.0 in Q2 2024 to a low of 33285000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 23916000.0 across 5 years, with a median of 24133000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 73.82% in 2024, then sank 142.4% in 2025.
• A 5-year view of Cash from Operations shows it stood at 29128000.0 in 2022, then advanced by 17.57% to 24009000.0 in 2023, then advanced by 25.31% to 17932000.0 in 2024, then fell by 23.49% to 22145000.0 in 2025, then tumbled by 35.22% to 29944000.0 in 2026.
• The last three Cash from Operations figures came in at 29944000.0 (Q1 2026), 22145000.0 (Q4 2025), and 31207000.0 (Q3 2025), per Business Quant data.